A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.

Item

http://www.wikidata.org/entity/Q41200024

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A meta-analysis of rate ratios ...... definitions for hypoglycaemia.

@en

type

Item

label

A meta-analysis of rate ratios ...... definitions for hypoglycaemia.

@en

prefLabel

A meta-analysis of rate ratios ...... definitions for hypoglycaemia.

@en

P1476

A meta-analysis of rate ratios ...... definitions for hypoglycaemia.

@en

P2093

B Zinman

http://www.w3.org/2001/XMLSchema#string

C Mathieu

http://www.w3.org/2001/XMLSchema#string

M L Wolden

http://www.w3.org/2001/XMLSchema#string

R Kapur

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.

A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function

Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-ta

P304

478-487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1111/DME.13002

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Simon Heller

P577

2015-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26484727

http://www.w3.org/2001/XMLSchema#string

P921

hypoglycemia

Insulin

P932

5064738

http://www.w3.org/2001/XMLSchema#string